Table 1.
Demographic and clinical characteristics of all eyes
| No. | Age | Sex | R/L | Follow up (Months) |
Initial Snellen BCVA |
Final Snellen BCVA |
Refractive error | META-PM classification (chorioretinal atrophy) | Height of SRF at first visit (μm) | Treatment PDT/ Intravitreal anti-VEGF injection |
Treatment response at final visit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Myopic CSC group | |||||||||||
| 1 | 43 | F | R | 11 | 20/50 | 20/32 | −17 | Patchy | 15 | 0/6 | Recurred |
| 2 | 43 | F | L | 11 | 20/32 | 20/25 | −14 | Patchy | 40 | Untreated | Not changed |
| 3 | 46 | M | R | 88 | 20/32 | 20/25 | −5.5 | Diffuse | 37 | Untreated | Disappeared |
| 4 | 27 | M | L | 5 | 20/25 | 20/20 | −6.5 | Diffuse | 48 | 1/9 | Complete |
| 5 | 67 | F | R | 93 | 20/100 | 20/63 | −7.75 | Diffuse | 97 | 1/0 | Complete |
| 6 | 56 | M | R | 1 | 20/80 | 20/63 | −4.75 | Diffuse | 112 | 1/0 | Not available |
| 7 | 40 | F | L | 7 | 20/25 | 20/32 | −8 | Diffuse | 136 | 1/2 | Incomplete |
| 8 | 69 | F | R | 64 | 20/40 | 20/63 | −6.25 | Diffuse | 67 | Untreated | Not changed |
| Myopic PNV group | |||||||||||
| 9 | 69 | F | L | 64 | 20/40 | 20/63 | −6 | Diffuse | 113 | 2/5 | Incomplete |
| 10 | 59 | F | R | 21 | 20/63 | 20/40 | −3 | Tessellated | 102 | 0/5 | Complete |
| 11 | 59 | M | R | 99 | 20/63 | 20/100 | −4.75 | Diffuse | 78 | 3/18 | Incomplete |
| 12 | 32 | F | R | 21 | 20/20 | 20/20 | −9 | Diffuse | 61 | 1/1 | Complete |
| 13 | 46 | F | L | 7 | 20/25 | 20/32 | −5 | Diffuse | 117 | 0/1 | Refractory |
| 14 | 46 | M | L | 12 | 20/32 | 20/25 | −12.5 | Diffuse | 42 | 0/5 | Incomplete |
| 15 | 48 | M | L | 55 | 20/20 | 20/20 | −9.5 | Diffuse | 35 | 0/2 | Complete |
R/L Right eye/Left eye, CSC Central serous chorioretinopathy, PNV Pachychoroid neovasculopathy, BCVA Best corrected visual acuity, META-PM META-analysis for Pathologic Myopia, SRF Subretinal fluid, PDT Photodynamic therapy, VEGF Vascular endothelial growth factor